Ramelteon
- Generic Name
- Ramelteon
- Brand Names
- Rozerem
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO2
- CAS Number
- 196597-26-9
- Unique Ingredient Identifier
- 901AS54I69
- Background
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
- Indication
用于失眠症，特别适用于治疗难以入睡型失眠症。
- Associated Conditions
- Insomnia
- Associated Therapies
- -
Treating Chronic Insomnia in Breast Cancer Patients
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2011-08-22
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 16
- Registration Number
- NCT00337272
- Locations
- 🇺🇸
Augusta Oncology Associates, PC, Augusta, Georgia, United States
🇺🇸Hematology Oncology Centers of the Northern Rockies, Billings, Montana, United States
🇺🇸Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 74
- Registration Number
- NCT00325728
Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2010-06-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 451
- Registration Number
- NCT00247390
Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 275
- Registration Number
- NCT00237497
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath